NCT05037188View on ClinicalTrials.gov

Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Coronavirus InfectionCOVID-19
Interventions
BIOLOGICAL

Low dose BCD-250 injection

A recombinant viral vector AAV5-RBD-S vaccine

BIOLOGICAL

High dose BCD-250 injection

A recombinant viral vector AAV5-RBD-S vaccine

BIOLOGICAL

Low dose or high dose BCD-250 injection

A recombinant viral vector AAV5-RBD-S vaccine

OTHER

Placebo injection

Placebo injection

Trial Locations (2)

Unknown

UNINOVA clinic, Saint Petersburg

X7 Clinical Research, Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY